Linda Goler Blount, MPH, to Join ICER Governance Board

March 20th, 2023|Categories: Featured, Industry News|Tags: , , , , |

Linda Goler Blount, MPH, has been elected to join the governance board of the Institute for Clinical and Economic Review. Blount has worked in health policy and is currently the president of the Black Women’s Health Imperative. She has built a career on addressing health disparities, especially those disproportionately affecting Black women and girls.

ICER Report Suggests Lower Price for Lecanemab Than Aduhelm

December 22nd, 2022|Categories: Featured, HEOR Feature, Industry News|Tags: , , , , |

The Institute for Clinical and Economic Review (ICER) has issued a report evaluating the value and cost-effectiveness of two amyloid-targeted therapeutics for Alzheimer's disease. Biogen and Eisai’s lecanemab was deemed by the agency to be cost effective if priced between $9,000 and $21,000, whereas Eli Lilly’s donanemab was valued between $14,500 and $46,900, although evidence was limited regarding the latter.

BioMarin’s Gene Therapy Roctavian More Cost-Effective in Hemophilia A than Genentech and Chugai’s Hemlibra

September 26th, 2022|Categories: Featured, Industry News|Tags: , , , , |

ICER has released a draft report that indicates Roctavian, BioMarin’s new gene therapy for hemophilia A, will beat the current antibody-based therapeutic Hemlibri. Unlike Hemlibri, which is a prophylactic, Roctavian restores the gene lacking in hemophilia A, factor VIII. The organization predicts that the one-time price of $2.5 million for Roctavian will be substantially lower than that of 12 years worth of Hemlibra at $640,000 annually.

ICER Review Casts Doubt on Value of Two ALS Drug Candidates

August 19th, 2022|Categories: Featured, Industry News|Tags: , , , , |

A new report by the Institute for Clinical and Economic Review (ICER) finds that 2 amytrophic lateral sclerosis (ALS) drug candidates from Amylyx and Mitsubishi Tanabe Pharma America have “low long-term value at their current suggested prices. Although the drugs both provide some benefits over the standard of care, the benefits do not justify the high price tag, the report notes.

ICER Report At a Glance: Beti-Cel for Beta Thalassemia

July 19th, 2022|Categories: Featured, Industry News|Tags: , , , |

Beta Thalassemia is a blood disorder that results in dangerously low levels of functional hemoglobin and requires expensive lifelong medical care, including regular blood transfusions. Beti-cel is a gene therapy by Bluebird Bio that can potentially cure the disorder by genetically modifying a patient's own hematopoietic stem cells (HSCs). The Institute for Clinical and Economic Review (ICER) has just released its assessment of Beti-cel, finding that it is effective and could save money on treatment, but more comprehensive long-term data would be necessary to determine the degree of the net health benefit over the current standard of care.

Go to Top